Related Experiment Video
Updated: Mar 29, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
10.6K
Correlation between CYP4F2 gene rs2108622 polymorphism and susceptibility to ischemic stroke
Chong Meng1, Juan Wang2, Wei-Ning Ge3
1Urgent Care Center, Shandong Provincial Hospital Affiliated to Shandong University Jinan 250021, Shandong, China.
International Journal of Clinical and Experimental Medicine
|December 3, 2015
Summary
The cytochrome P450 4F2 (CYP4F2) V433M gene variant (rs2108622) is associated with an increased risk of ischemic stroke. This finding suggests CYP4F2 may be a susceptibility gene for this condition.
Area of Science:
- Genetics
- Neurology
- Pharmacogenomics
Background:
- Ischemic stroke is a leading cause of disability and death worldwide.
- Genetic factors play a significant role in stroke etiology.
- The cytochrome P450 4F2 (CYP4F2) gene is involved in various metabolic processes, including arachidonic acid metabolism, which is relevant to vascular health.
Purpose of the Study:
- To perform a meta-analysis investigating the association between the CYP4F2 rs2108622 (V433M) gene polymorphism and the risk of ischemic stroke.
Main Methods:
- A systematic literature search was conducted for case-control studies on the CYP4F2 V433M polymorphism and ischemic stroke.
- Studies published before January 2015 were included.
- Meta-analysis was performed using RevMan 5.2 software, selecting the best genetic model and appropriate effect model based on heterogeneity tests.
Main Results:
- Six studies were included in the meta-analysis.
- The recessive genetic model (VM + MM vs. VV) was identified as the best fit.
- A significant association was found between the CYP4F2 V433M polymorphism and ischemic stroke (OR = 1.37, 95% CI: 1.21–1.54, P < 0.001), indicating an increased risk compared to the wild-type VV genotype.
Conclusions:
- The CYP4F2 V433M polymorphism may represent a genetic susceptibility factor for ischemic stroke.
- Further research is warranted to elucidate the precise mechanisms underlying this association.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
109
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
158
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
158
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
118
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
118
01:29Pharmacogenomics: Identification of New Drug Targets
76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
01:05Single Nucleotide Polymorphisms-SNPs
19.8K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.8K